USD 6.55 billion
Report ID:
SQMIG35J2075 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|Tables:
71
|Figures:
65
Global Cancer Pain Market size was valued at USD 6.55 billion in 2022 and is poised to grow from USD 6.92 billion in 2023 to USD 10.70 billion by 2031, growing at a CAGR of 5.6% in the forecast period (2024-2031).
The expansion of the global cancer pain market is primarily propelled by factors including the growing cancer prevalence, an aging population, increased healthcare spending, and augmented research and development efforts by healthcare enterprises.
In 2020, for instance, the American Cancer Society reported approximately 1.8 million new cancer cases and around 606,520 cancer-related deaths in the U.S. Colorectal cancer saw about 1,065,960 new cases worldwide that same year, according to the International Agency for Research on Cancer.
Older individuals are more susceptible to various cancers due to age-related effects and genetic mutations. The National Cancer Institute indicates median diagnosis ages of 61 for breast cancer, 68 for colorectal cancer, 70 for lung cancer, and 66 for prostate cancer.
US Cancer Pain Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 6.55 billion
Largest Segment
Lung Cancer
Fastest Growth
Breast Cancer
Growth Rate
5.6% CAGR
To get more reports on the above market click here to Buy The Report
The global cancer pain market is segmented on the basis of drug type, disease indication, region. By drug type, the market is segmented into opioids, morphine, fentanyl, others, non-opioids, acetaminophen, non-steroidal anti-inflammatory drugs (nsaids), nerve blockers. By disease indication, the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, others. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.
Cancer Pain Market Analysis By Drug Type
In 2022, the market was largely led by the opioids segment, a trend projected to persist during the forecast period. This dominance is attributed to the growing prevalence of intense cancer-related pain, the escalating use of opioids for cancer pain management, and a robust pipeline of such drugs. Conversely, the non-opioids sector is anticipated to experience significant market expansion in the forecast period due to factors such as the widespread availability and cost-effectiveness of these medications.
The opioids category's stronghold can be attributed to the increasing incidence of severe cancer-related pain and the growing adoption of opioids as a primary method of pain management. The presence of a strong pipeline for opioid-based drugs is further bolstering this segment's prominence. Conversely, the non-opioids division is poised for substantial growth due to factors like the ready accessibility of these drugs, making them an attractive option for mild to moderate cancer pain cases. Additionally, the cost-effectiveness of non-opioid medications adds to their appeal and is anticipated to contribute significantly to their market traction during the forecast period.
Cancer Pain Market Analysis By Disease Indication
In 2022, the cancer pain market was largely steered by the lung cancer segment, and this dominance is projected to endure over the forecast period. The prevailing influence of this segment can be attributed to several factors, including the rising prevalence of lung cancer cases, a heightened occurrence of pain linked to lung cancer, and the availability of efficacious analgesics tailored to address the specific pain associated with this type of cancer.
Lung cancer's preeminence in driving the market is driven by its escalating prevalence and the inherent pain challenges accompanying the disease. The substantial pain experienced by lung cancer patients has underscored the demand for targeted pain management strategies, making this segment a prominent driver of the market. Additionally, the development of specialized analgesics that effectively target the unique pain patterns associated with lung cancer has further solidified the segment's dominant position.
Conversely, the breast cancer segment is poised for significant market growth during the forecast period. This projection can be attributed to the increasing prevalence of breast cancer, a commonly diagnosed malignancy among individuals. The adoption of pain analgesics in breast cancer treatment regimens has gained traction owing to the substantial discomfort often experienced by patients. As a result, the breast cancer segment is expected to witness noteworthy expansion, driven by the imperative to alleviate pain and enhance the overall quality of life for breast cancer patients through targeted pain management interventions.
To get detailed analysis on other segments, Request For Free Sample Report
In 2022, North America played a pivotal role in the cancer pain market, capturing a substantial share, and this influential position is anticipated to persist throughout the forecast period. The region's continued prominence is underpinned by several factors including the escalating prevalence of cancer cases, continuous technological advancements in the healthcare sector, the convenient accessibility of pain management therapies, and the availability of top-tier chemotherapy treatment options. These factors collectively contribute to North America's stronghold in driving the growth of the cancer pain market.
Notably, Asia-Pacific is projected to exhibit the highest CAGR of 6.0%. This robust growth trajectory is attributed to multiple factors that are transforming the landscape of cancer pain management in the region. The rapid increase in cancer prevalence within Asia-Pacific has necessitated an augmented focus on effective pain management solutions. Furthermore, the region is experiencing a surge in its elderly population, a demographic more prone to cancer incidence, which further emphasizes the demand for advanced pain management interventions. Additionally, a heightened awareness pertaining to the importance of early cancer screening has gained momentum, contributing to the increased demand for pain management strategies. These combined forces are driving Asia-Pacific's impressive growth in the cancer pain market, making it a significant contender in shaping the future of cancer pain management.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Cancer Pain Market Drivers
Advancements in Medical Technology
Increased Healthcare Expenditure
Cancer Pain Market Restraints
Adverse Effects of Pain Medications
Stigma Around Opioid Use
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape of the global cancer pain market is characterized by a diverse array of pharmaceutical and healthcare companies striving to offer innovative solutions for effective pain management. Established players such as Pfizer, Johnson & Johnson, Purdue Pharma, and Novartis maintain a strong presence, leveraging their extensive research capabilities and product portfolios. These companies often collaborate with medical institutions to advance pain management technologies and therapies.
The market also witnesses the emergence of smaller, specialized firms like Heron Therapeutics, who focus on developing novel drug delivery systems and non-opioid alternatives. Technological advancements, personalized treatment approaches, and telemedicine integration are reshaping the landscape. Moreover, the trend towards patient-centric care is fostering the growth of startups and initiatives that emphasize comprehensive pain relief and improved quality of life for cancer patients. As the market continues to evolve, competition intensifies, encouraging continuous innovation to address the multifaceted challenges of cancer pain management.
Cancer Pain Market Top Player’s Company Profiles
Cancer Pain Market Recent Developments
In March 2024, Metis Global Partners LLC unveiled that it raised its stake in Microsoft Co. by 16.3% during the third quarter, as detailed in its most recent exposure with the SEC.
In February 2024, Radformation, a main supplier of radiation oncology software solutions, declared its strategic partnership with Icon Group (Icon), a worldwide leader in comprehensive cancer care. This collaboration unites the aptitude of the two organizations to change disease care through imaginative work processes and high-level software solutions.
In January 2024, Quibim, an organization working on changing imaging data into significant actionable data for cancer growth and treatment responses, collaborated with Merck KGaA. The collaboration means fostering high-level imaging-based diagnostics for accurate medication.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Product types team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global cancer pain market analysis, the global cancer pain market encompasses a dynamic landscape driven by the increasing prevalence of cancer cases worldwide. This market focuses on providing effective pain management solutions for individuals undergoing cancer treatment or experiencing cancer-related pain. Factors such as advancements in medical technology, rising healthcare expenditures, and the growing geriatric population contribute to the expansion of this market. Pharmaceutical and healthcare companies, both established giants like Pfizer, Johnson & Johnson, and Novartis, as well as innovative startups like Heron Therapeutics, play a pivotal role in developing novel pain relief drugs, therapies, and drug delivery systems. The market's emphasis on personalized and patient-centric approaches, coupled with the integration of telemedicine and digital solutions, is transforming how cancer pain is managed. The shift towards non-opioid alternatives, multimodal strategies, and the integration of palliative care reflects a broader focus on enhancing the overall quality of life for cancer patients. As the market evolves, collaborations between pharmaceutical firms, medical institutions, and startups continue to shape a diverse landscape committed to alleviating the burden of cancer-related pain.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 6.55 billion |
Market size value in 2031 | USD 10.70 billion |
Growth Rate | 5.6% |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Cancer Pain Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cancer Pain Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cancer Pain Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cancer Pain Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35J2075
sales@skyquestt.com
USA +1 351-333-4748